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Abstract The aim of this study was to evaluate the
in vitro and in vivo biocompatibility of artificial bone based
on vancomycin loaded mesoporous silica nanoparticles and
calcium sulfate composites. In vitro cytotoxicity tests by
cholecystokinin octapeptide (CCK-8) assay showed that
the 5 %Van-MSN-CaSO4 and Van-CaSO4 bone cements
were cytocompatible for mouse osteoblastic cell line
MC3T3-E1. The microscopic observation confirmed that
MC3T3-E1cells incubated with Van-CaSO4 group and
5 %Van-MSN-CaSO4 group exhibited clear spindle-
shaped changes, volume increase and maturation, showing
that these cements supported adhesion of osteoblastic cells
on their surfaces. In addition, the measurement of alkaline
phosphatase activity revealed the osteoconductive property
of these biomaterials. In order to assess in vivo biocom-
patibility, synthesized cements were implanted into the
distal femur of twelve adult male and female New Zealand
rabbits. After implantation in artificial defects of the distal
femur, 5 %Van-MSN-CaSO4 and Van-CaSO4 bone
cements did not damage the function of main organs of
rabbits. In addition, the Van-MSN-CaSO4 composite
allowed complete repair of bone defects with new bone
formation 3 months after implantation. These results show
potential application of Van-MSN-CaSO4 composites as
bone graft materials for the treatment of open fracture in
human due to its mechanical, osteoconductive and poten-
tial sustained drug release characteristics and the absence
of adverse effects on the body.
1 Introduction
Bone transplants are broadly used in the treatment of open
fractures, especially for providing mechanical or structural
support and promoting the bone tissue formation [1, 2].Due to
high rate of bone infections and infection-related complica-
tions in open fractures, it is necessary to load bone implants
with antibiotics for treating osteomyelitis or eradicating,
reducing or preventing contaminations [3]. In addition, the
synthetic bone material must be safe and suitable for
implantation in vivo. Calcium sulfate has got a long clinical
history as bone biomaterial because apart from providing
structural support, it holds good biocompatibility, osteoin-
ductivity and bioabsorbability and can serve as a vehicle for
delivery and local release of antibiotics [4–8]. For instance,
Kelly et al. (2001) successfully used surgical grade calcium
sulfate pellets as convenient and safe bone graft substitute for
the treatment of patients with bone defects [9]. Additional
studies on bone graft substitutes have equally confirmed the
biocompatibility of calcium sulfate composites and suggested
their use as suitable bone implantmaterial for in vivo therapies
[10, 11]. In our previous work, we used calcium sulfate par-
ticles impregnated with vancomycin for the treatment of
infected bone defects of 28 cases of open fractures among
which 26 cases were followed up, and found that this material
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and can successfully promote the fracture healing [12].
However, we recorded some shortcomings, such as low drug
delivery and drug release ability and the difficulty to achieve
the maintenance of drug concentration. Therefore, a drug
deliverymaterial,which can sustain drug release, is needed for
the clinical treatment.
In the recent years, the use of mesoporous silica nanopar-
ticles (MSNs) has been extended in biomedical fields such as
cancer therapy, drug and gene delivery, biosensors, and
enzyme immobilization [13]. MSNs can be used as drug
carriers, can sustain delivery and local release of drugs and has
good biocompatibility. For example, Kempen et al. [8]
showed that mesenchymal stem cells (MSCs) labeled with
MSN had no cytotoxicity at the 250 lg/mL concentration
required for labeling. Itwas also reported thatmulti-functional
MSNs coated with poly (N-isopropylacrylamide) (PNIPAM)
composite nanomaterials can easily carry guestmolecules into
human breast carcinoma cells (MCF-7) and display minute
cytotoxicity to the cells [14]. Previously, a biocompatible
silica-based nanoparticles synthesized by incorporating the
bone-forming peptide (BFP) into MSNs showed better cell
proliferation and osteogenic differentiation and could be used
as a bioactive material for bone repairing, bone regeneration,
and bio-implant coating applications [15]. Most of drugs are
loaded into the pores of MSN and can only be released by
diffusion. This significantly reduces and retards the local drug
release and subsequently improves drug bioavailability.
However, MSN itself is in a powder state, which makes it
difficult to be directly used as bone implant material. Up to
now, studies have shown that by using MSNs loading rate of
5 %, artificial bone materials with a relatively good solidity
can be obtained [11, 16]. Therefore, by combiningMSNs and
calcium sulfate, a new type of robust artificial bone material
for bone repair with sustained release effect can be obtained.
However, to potentiate this material for suitable use in the
human body, it is primarily necessary to investigate its
impacts on the organisms.
Therefore, in the present study, we aimed to examine the
biocompatibility of the previously synthesized artificial bone
based on vancomycin loaded mesoporous silica nanoparticle
and calcium sulfate composites [17] in order to provide
experimental basis for its application as a bone graftmaterials.
2 Materials and methods
2.1 In vitro biocompatibility evaluation of bone
cements
2.1.1 Materials
The cells of murine osteoblast MC3T3-E1 were purchased
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). Penicillin, streptomycin, fetal bovine
serum (FBS) and a-MEM medium were all purchased from
Hyclone (Logan, UT). The artificial bone based on van-
comycin loaded MSNs and calcium sulfate composites was
obtained from the Key Laboratory ofMolecular Engineering
of Polymers of FudanUniversity. Themedical grade calcium
sulfate was purchased from Tianjin Sheehan biochemical
technology co., LTD. Cholecystokinin octapeptide (CCK-8)
was purchased from Peptide Institute (Minoh, Japan) while
alkaline phosphatase (ALP) detection kit was provided by
Nanjing Jiancheng Bioengineering Institute.
2.1.2 Preparation of leaching solutions
Bone cement based on vancomycin loaded MSNs and
calcium sulfate composites (5 %Van-MSN-CaSO4) [11]
and calcium sulfate impregnated with vancomycin (Van-
CaSO4) bone implant [12] were prepared as described
elsewhere [11, 12]. A certain amount of prepared Van-
MSN-CaSO4 or Van-CaSO4 was sterilized under ultravio-
let radiation, soaked in a-MEM medium supplemented
with 10 % FBS at a soaking rate of 0.1 g/ml according to
ISO10993.5 standards and incubated hermetically at 37 C
for 72 h. Subsequently, the obtained leaching solutions
were filtered and stored at 4 C until use.
2.1.3 Cell cultivation, cytotoxicity evaluation and alkaline
phosphatase activity
MC3T3-E1 cells were cultured in a-MEM culture medium
supplemented with 10 % (v/v) FBS (Hyclone, USA).
Incubation was performed in a CO2 incubator (5 % CO2,
95 % air). The cells were subcultured every 2 or 3 days.
To evaluate the cytotoxicity of artificial bone compos-
ites, third-generation MC3T3-E1 cells were seeded in
96-well plates (4000 cells/well containing 100 ll of a-
MEM medium in 5 % CO2 controlled air incubator at
37 C for 24 h to allow cell attachment. After cell adhesion
on the bottom of the wells, the culture medium was aspi-
rated and changed into fresh medium supplemented with
dilutions of the leaching solutions (100, 50 and 25 %
concentrations of filtrated leaching solutions) prepared as
indicated in Table 1. Six wells were seeded for each
dilution and the negative control for which no leaching
solution was added. After 1, 2, 3 and 5 days cultivation,
cells were washed twice with fresh a-MEM medium and
replaced by 100 ll of the same medium plus 10 ll of
CCK-8. After further cultivation for 2 h, we measured the
absorbance at 450 nm using the ELISA plate reader
according to the guidelines of CCK8 assay kit.
For ALP assay, the cells were cultured under the same
conditions as that of the CCK8 assay. After 3 and 5 days,
ALP activity was measured by spectrophotometric methods
64 Page 2 of 11 J Mater Sci: Mater Med (2016) 27:64
123
at 520 nm using an ALP assay kit according to the man-
ufacturer’s protocol.
2.2 In vivo biocompatibility evaluation of bone
cements
2.2.1 Animal population
Twelve adult male and female New Zealand rabbits, with a
mean weight of 2.5 kg and ages ranging from 4 to 5 months
were divided into control group (n = 3), simple MSNs
implant group (n = 3), 5 %Van-MSN-CaSO4 implant group
(n = 3) and CaSO4 implant group (n = 3). All procedures
were performed in accordance with standard guidelines as
described in the Guide for the Care and Use of Laboratory
Animals (US National Institutes of Health 85-23, revised
1996). All animal protocols were agreed by the local Institu-
tional Animal Care and Use Committee of Tongji University.
2.2.2 Surgical procedure
The surgical procedure adopted for implantation of bone
materials is depicted in Fig. 1. Prior to surgical processes,
general anesthesia was achieved by intravenous injections of
pentobarbital at a dose of 1 ml/kg body weight whereas 2 %
lidocaine was used for local anesthesia in the subcutaneous
area of the insertion site. After shaving, povidone iodine
disinfection and placing surgical drapes, about 3 cm longi-
tudinal incision was achieved in the area of the distal
femoral diaphysis, followed by a step by step separation to
expose the lateral condyle cortical bone. Thereafter, bone
defects (ø 3 mm, depth 2 mm) were created by drilling
Table 1 Experimental groups and interventions
Experimental group Implementation plan
A (100 %Van-MSN-CaSO4 original leaching solution) 3 ml Van-MSN-CaSO4 original solution
B (50 %Van-MSN-CaSO4 dilution) 1.5 ml A ? 1.5 ml a-MEM medium supplemented with 10 % FBS
C (25 % Van-MSN-CaSO4 dilution) 0.5 ml A ? 1.5 ml a-MEM medium supplemented with 10 % FBS
D (100 %Van-CaSO4 original leaching solution) 3 ml Van-CaSO4 original solution
E (50 %Van-CaSO4 dilution) 1.5 ml D ? 1.5 ml a-MEM medium supplemented with 10 % FBS
F (25 %Van-CaSO4 dilution) 0.5 ml D ? 1.5 ml a-MEM medium supplemented with 10 % FBS
G(negative control) 3 ml a-MEM medium supplemented with 10 % FBS
Fig. 1 Images of the surgical procedures adopted for implantation of artificial bones. a Shaving and desinfection, b perforation to create bone
defect, c implantation of artificial bones in created defects, d sutures
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perpendicularly to the direction of the cortical bone, with
cautious avoidance of the penetration in the lateral cortex.
After washing the wound with physiological water, implant
materials corresponding to experimental and control groups
were inserted. For the blank control group the wound was
simply open without implantation of bone materials. Finally,
following disinfection, surgical sites were closed using
resorbable sutures and rabbits woken up after caging.
2.2.3 Samples collection
Blood samples were taken respectively at 1, 2 and
3 months after operation, centrifuged at 3000 g for 5 min
for serum separation and cryopreserved at -80 C.
For collection of bone samples and main viscera, animals
were sacrificedafter 12 weeksby intravenous injectionof20 ml
of air. Distal femurs of rabbits containing defects and major
rabbit organs (heart, liver, spleen, lung, and kidney) were har-
vested en bloc after operation and immersed in paraformalde-
hyde until further processing for histological analysis. In
histological analysis of viscera, samples were collected after
sacrifice of normal animals without implants or defects.
2.2.4 Histological and histopathological evaluation
The conventional HE staining was used for microscopic
examinationof paraffinembeddedhistological sections ofmain
organs (5–6 microns thickness). Bone specimens were decal-
cified and HE stained. The decalcified sections were observed
under a light microscope (Nikon Eclipse 50i) with a 10x
magnification objective. Eight nonconsecutive images of each
HE-stained specimen section were blindly analyzed by one
expert observer. The images were digitally captured (Nikon
H500S) and visualized with Image Pro-Plus 6.0 for Windows.
2.2.5 Micro-CT examination
The micro-CT analysis was performed on samples from the
lateral femur condyle (including the defect with implant
material) using the high-resolution micro-CT system Sky-
scan 1076 (SkyScan, Aartselaar, Belgium). The X-ray
source was an air-cooled, sealed Hamamatsu 100/250 tube
with a focal spot size\8 lm. The X-ray tube was run at
source voltage of 40 kV and source current of 250 lA
without filter. The X-ray detector consisted of a Princeton
Instruments camera with camera pixel size of 12.60 lm
and camera X/Y Ratio of 1.0000. NRecon program version
1.6.9.4 was employed for reconstruction.
The quality of new bone was evaluated based on pictures
analyzed by CTAn, a micro-CT analysis program. The bony
tissue of the new bone was analyzed with a ROI (region of
interest) at a width of 0.99 mm and a height of 2.48 mm.
The bone portion containing implants (defects zone) was
analyzed using an ROI at a size of 0.97 mm and a height of
2.48 mm. For quantification of the quantity and quality of
the new bone, we evaluated the percent bone volume (BV/
TV) and specific bone surface (BS/BV) as well as trabecular
thickness (TbTh) and trabecular number (TbN).
2.2.6 Statistical analysis
The experimental data were expressed as mean ± standard
deviation. SPSS20.0 statistical software was used for sta-
tistical analysis using one way-ANOVA for comparison
between multiple samples. Multiple intra-groups compar-
isons were achieved through SNK test. Statistical signifi-
cance was evaluated with a p-values cutoff of\0.05.
3 Results
3.1 In vitro biocompatibility evaluation of bone
cements
3.1.1 Cytotoxicity test
In order to evaluate the cyto-compatibility of bone implant
materials, the CCK-8 cytotoxicity assay was performed after
1, 2, 3 and 5 days cultivation of MC3T3-E1 cells with dif-
ferent concentrations of leaching solutions stemmed from
bone implants. As displayed in Fig. 2a, an increase in absor-
bance from day 1 to day 7 was recorded, which indicates cell
viability with both the Van-CaSO4 and Van-MSN-CaSO4
implant materials. Moreover, the proliferation behaviors of
cellswithdifferent implantmaterialswerevery similar to each
other in every measurement point. Indeed, comparatively to
the negative control group and the Van-CaSO4 artificial bone
control group, Van-MSN-CaSO4 implant material had no
inhibitory effect on the proliferation of mice osteoblasts
(P[ 0.01) and there was no significant difference between
groups or between concentration groups (P[ 0.01).
3.1.2 Alkaline phosphatase assay
To assess the effect of bone cements on osteoblast differ-
entiation, we determined the ALP activity of MC3T3-E
cells after 3 and 5 days cultivation. The measurement of
ALP activity (Fig. 2b) showed significant differences
between the blank control group and the leaching solutions
with dilution rates C50 %. Between leaching solutions
with dilution rate of 25 % and the blank control, no sta-
tistically significant differences were observed. No signif-
icant differences were observed among Van-MSN-CaSO4
and Van-CaSO4 leaching solutions. Nevertheless, MC3T3-
E1 cells produced increasing ALP activity with the
increase of the concentrations of leaching solutions. This
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result indicated the osteoconductivity of both kinds of bone
cements which must be attributed to Ca2? ions in a dose-
dependent way. We could additionally notice an increase
of ALP activity with the incubation time. The findings
similarly revealed improved differentiation of MC3T3-
E1cells seeded in the presence of different concentrations
of Van-MSN-CaSO4 or Van-CaSO4.
3.1.3 Effect of bone cements on cytological changes
The cytological examination of MC3T3-E1 osteoblasts
incubated with media containing prepared leaching solutions
is depicted on Fig. 3. The microscopic observation of cell
morphological changes revealed that cells incubated with
Van-CaSO4 and 5 %Van-MSN-CaSO4 leaching solutions
were mature, clearly fusiform with increased volume. Cells
in the control group without leaching solution remained
polygonal and did not show obvious cell differentiation.
This suggested that studied bone cements supported adhe-
sion of osteoblastic cells on their surfaces. Altogether, the
results of the in vitro biocompatibility assessment showed
that the Van-MSN-CaSO4 implant presents no obvious
cytotoxicity and could be used for clinical applications.
3.2 In vivo evaluation of the biocompatibility
of bone cements
3.2.1 Macroscopic observations
In order to evaluate the efficacy of Van-CaSO4 and
5 %Van-MSN-CaSO4 implants in defects repair, animals
were killed 3 months after bone implantation. After
surgery lower extremities of femur containing defects were
collected and macroscopically examined. The photographs
are presented in Fig. 4. The results showed that in the MSN
implant group, most of the bone defects was filled with
SiO2 granules. No bony connection was seen in any of the
3 rabbits, but partial bone formation was observed
(Fig. 4a). In Van-CaSO4 group, most of the defect was
healed and only slight bone formation was found in sites of
the defects (Fig. 4b). In the Van-CaSO4-MSN group,
complete healing of the segmental defect was observed in
all 3 rabbits. In addition remarkable new bone formation
(Fig. 4c) and no residual CaSO4 was found in the 3 rabbits.
In the control group without implant, no new bone for-
mation was found in sites of the defects (Fig. 4d).
3.2.2 Micro-CT analysis
As shown in Fig. 5, the micro-CT analysis of distal femur
samples collected 3 months after implantation further con-
firmed the macroscopic observation results. Descriptive
statistics for BV/TV, BS/BV, TbTh and Tb.N were deter-
mined. The results showed that (Fig. 6), the mean relative
BV/TV (newly formed bone volume density) were higher at
12 weeks. The adjusted mean BV/TV were 22.92, 20.30,
28.52 and 30.65 % for control, Van-MSN, Van-MSN-
CaSO4 and Van-CaSO4 implant materials, respectively. The
BS/BV value was 15.77 m-1 for the control, 16.05 for Van-
MSN, 9.69 m-1 for Van-MSN-CaSO4 and 10.32 m
-1 for
Van-CaSO4. The differences of BV/TV and BS/BV between
Van-MSN-CaSO4 and Van-CaSO4 implant materials were
not statistically significant. The trabecular thickness (TbTh)
was smaller in the control and Van-MSN groups compared
Fig. 2 In vitro analysis of the biocompatibility of different artificial bone leaching solutions measured after 5 days cultivation: a Proliferation of
MC3T3-E1 cells, b phosphatase alkaline (ALP) activity of MC3T3-E1 cells
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to implant groups but no statistically significant differences
were observed between groups.
3.2.3 Histological evaluation
The HE staining and histological observation of decalcified
bones including the defect site was performed 12 weeks
after implantation. The results (Fig. 7) revealed that in the
rabbits femur bone defects, distinctive lamellar bone
developed at the host bone-implant boundary and within the
spongy spaces of the Van-MSN-CaSO4 implants (Fig. 7b),
as well as in the Van-CaSO4 implants (Fig. 7c). Small
amount of new bone were similarly formed in Van-MSN
implants (SiO4 alone) (Fig. 7a) while only loose connective
tissue were noticed in the gap control group (Fig. 7d).
3.2.4 Pathomorphological observation of viscera
In order to evaluate the toxicity of implants material, HE
staining and histopathological observation of sections of
main organs before and after implantation of Van-MSN-
CaSO4 were performed. The result (Fig. 8) showed no
visible significant differences of the effect of different
implant groups on heart, liver, spleen, lung, kidney and
other important organs. This suggested that Van-MSN-
CaSO4 implant is biocompatible and can be used as a safe
bone implant for treatment of bony defects.
3.2.5 Hematological index
In order to further understand the cytotoxicity of artificial
bone composite from biochemical point of view, we
additionally determined the hematological index of studied
rabbits. As shown in Table 2, no statistically significant
difference was observed between groups, which further
confirms the biocompatibility of Van-MSN-CaSO4.
4 Discussion
Good biocompatibility is an imperative parameter to take
into account during the development of bone implant
materials. In the present study, the in vitro and in vivo
evaluation of Van-MSN-CaSO4 and Van-CaSO4
Fig. 3 Cytological analysis of morphological changes of MC3T3-E1 cells after incubation with different bone cements
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Fig. 4 Images depicting the macroscopic state of bony defects 3 months after implantation. a pure MSN (SiO2) implant group, b van-CaSO4
implant group, c van-MSN-CaSO4 implant group, d pure control group of rabbits without implant (Group 4)
Fig. 5 Micro-CT images of femur regions containing bony defects 3 months after implantation. a Pure MSN (SiO2) implant group, b van-
CaSO4 implant group, c van-MSN-CaSO4 implant group, d pure control group of rabbits without implant (Group 4)
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biocompatibility was performed in order to assess their
safety and potential usefulness in bone transplantation.
The cell proliferation experiment revealed that there was
no significant difference of the absorbance of MC3T3-E1
cells incubated with leaching solution originated from Van-
MSN-CaSO4 composite when compared with Van-CaSO4
control group (P\ 0.05). The optical density (OD) values
increased progressively until 5 days cultivation showing
that the proliferation activity of MC3T3-E1 cells was not
significantly affected. This result implies that Van-MSN-
CaSO4 composite had no obvious toxic effects on osteo-
blasts as it was previously reported by Chung et al. [18]
who found that MSNs have no significant effect on the
proliferation and differentiation of human bone marrow
mesenchymal stem cells.
Osteoblasts are main functional cells of bone formation
responsible for bone matrix synthesis, secretion and min-
eralization. As bone implant, MSNs may directly affect the
osteogenesis effect of osteoblasts. ALP, as a key indicator
of osteoblast maturation and differentiation [19], is of great
significance in evaluating the degree of differentiation of
osteoblasts. In this study, we found that ALP activity
increased significantly (P\ 0.05) over the incubation time
in cultures of MC3T3 cells incubated with 5 %MSNs-
CaSO4 leaching solution compared with the blank control
group. In addition, ALP activity increased obviously with
the increase of leaching solution concentration. More
importantly, no significant differences were recorded
between 5 % MSNs-CaSO4 composite leaching solution
and the CaSO4 leaching solution control group. This fur-
ther illustrates that corresponding leaching solutions did
not negatively affect osteoblast proliferation but promoted
cell morphological changes and differentiation. These
Fig. 6 Descriptive statistics for BV/TV, BS/BV, TbTh and TbN
measured by micro-CT
Fig. 7 Stained histology of femur regions containing bony defects 3 months after implantation. a Pure MSN (SiO2) implant group, b van-CaSO4
implant group, c van-MSN-CaSO4 implant group, d pure control group of rabbits without implant (Group 4)
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effects are likely attributable to the Ca2? solution which
was previously reported to have osteoconductive effect [19,
20].
The effect of MSNs implants on rabbit’s bone tissue
fractures healing process, which is similar to that of human,
have not been reported so far. The macroscopic observation
and Micro-CT analysis showed that after the implantation
of Van-MSN-CaSO4 artificial bone composite, complete
healing of bony defects was observed 12 weeks after
surgery compared with Van-CaSO4 composite and the
blank control group without implant. This result shows that
Van-MSN-CaSO4 implant did not delay the healing of
bony defects or hinder bone tissue repair, which indicates
its potential application as a good drug carrier implant able
to concurrently accomplish bone defects filling and local
drug release.
After implantation in the distal femur, CaSO4 can be
absorbed and degraded in the body, vancomycin can enter
Fig. 8 Histopathological analysis of lung, spleen, kidney, heart and liver before and 3 months after implantation of Van-MSN-CaSO4 implant
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in the metabolism of liver and kidney but whether SiO2
nanoparticles can produce certain toxicity effect to the
body or not is unclear. Therefore, we further investigated
the toxicity of bone implant on rabbit internal organs by
histopathological observation of major organs. In addition
blood biochemical index of the seemingly damaged func-
tion of liver and kidney were determined in order to
understand the cytotoxicity of artificial bone composites
from biochemical point of view. The result showed no
significant pathological effect changes in heart, liver,
spleen, lung and kidney. According to the blood bio-
chemical test, there was no significant difference between
studied groups and Van-MSN-CaSO4 material did not
cause the body to produce apparent rejective reaction or
inflammation. Therefore, the Van-MSN-CaSO4 bone
implant can be used as the carrier of vancomycin without
producing obvious toxic effect. According to previous
studies, direct injections of MSNs by peritoneal or
intravascular ways do not produce the same effects. In this
study, the local implantation of bone materials did not
cause much release of MSNs into the bloodstream and
could not therefore instigate the damage of main organs.
We employed 5 %Van-MSN-CaSO4 rather than using a
larger dose of MSNs because previous studies [11, 21]
showed that this dose of MSNs is enough to maintain
vancomycin concentration and drug release for long time.
In addition this concentration is greater than the van-
comycin minimal inhibitory concentrations (MIC) of S.
aureus which is responsible for the common bacterial
infection of bone. On the other hand, this proportion of
MSNs does not affect the bone filling potential of CaSO4
material [12]. One limitation of the present work could be
that we did not measure the in vivo release of vancomycin,
therefore it would be inaccurate to affirm that the use of
MSN allows for sustained drug release. However, this issue
was already studied in our previous research work where
we thoroughly investigated the drug release efficiency of
VAN-MSN-CaSO4 cement [17].
In the process of bone formation, additionally to the
osteoblasts, there are many factors that affect bone healing,
such as osteoclasts and bone marrow mesenchymal stem
cells [22, 23]. We need to further study the toxic effects of
MSN materials on these cells, as well as the interaction
between silica nanoparticles and organelles. We similarly
need to further study safety dose of MSNs after implan-
tation as bone filling material.
5 Conclusion
Vancomycin loaded MSNs-CaSO4 artificial bone material
(MSNs mass fraction of 5 %) showed no obvious cyto-
toxic effect on MC3T3-E1 cells. The local implantation of
this bone implant materials did not delay fracture healing
and had no obvious damage effects on the function of
main organs of rabbit. In conclusion, Van-MSN-CaSO4
artificial bone material has good biocompatibility and
could be used for the treatment of bone defects in human
since fracture healing in the rabbit is similar to that of
human.
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Table 2 Serum biochemical
indexes of each rabbit measured
before and after implantation of
bone composites. G1: group1
(pure MSN (SiO2) implant
group), G2: Group 2 (Van-
CaSO4-MSN (SiO2–CaSO4)
implant group) G3: Group 3
(CaSO4 implant group), G4:
Group 4 (the control group
without implant), N1–N12:
rabbit numbers
Sample number ALT AST GGTLI(r-GT) UREA CREA ALP
G1N1 30.1 26.7 10.2 11.7 68.5 68.7
G1N2 62.6 20.2 12.3 8.8 73.2 46.4
G1N3 60.5 15.1 12.3 10.6 81.7 49.4
G2N4 33 22.2 8.2 7.3 70.1 57.5
G2N5 59.8 25 9.5 11.5 74.4 57.6
G2N6 45.4 23.5 7.5 10.3 65.3 87.1
G3N7 28.7 17.7 8.3 12.5 66.4 44.3
G3N8 41.9 21.2 8.5 12.2 83.2 90.5
G3N9 65.9 23.2 6.1 6.9 77.6 42
G4N10 61.4 35.2 11.5 11.3 54.7 63.3
G4N11 41.9 20.7 10.6 12.5 98.9 30.7
G4N12 77.8 30.9 9.6 7.1 103.8 31.6
Before operation 22.2 14 8.1 6.3 52.8 63
G2-2 days after operation 33.5 56.4 8 9.3 58.6 33.4
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